Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ: ADMA) failed to manage ADMA Biologics in an acceptable manner, breaching their fiduciary duties to ADMA Biologics, and whether ADMA Biologics and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know:

• On March 24, 2026, Culper Research published a short report on ADMA Biologics, alleging channel stuffing and undisclosed related party transactions.
• If you own ADMA Biologics common stock, join our investigation on behalf of ADMA Biologics and its shareholders by filling out the form here.

If you own ADMA Biologics common stock and you wish to discuss this investigation—at no cost for you—please contact attorney Joe Pettigrew toll-free at (844) 818-6982 or jpettigrew@scott-scott.com.

About this investigation – FAQ:

Q1: What is this ongoing investigation into ADMA Biologics about?

A: According to our investigation, owners of ADMA Biologics common stock have been impacted by misstatements regarding alleged channel stuffing and undisclosed related party transactions. Scott+Scott has a decades-long track record in fighting for corporate governance and monetary recoveries on behalf of companies and their shareholders.

Q2: How does this Scott+Scott investigation work?

A: Joining our investigation is easy and at no cost for you. By filling out the form here, we will let you know your rights as an ADMA Biologics shareholder, and how the process works and what you can expect. If you currently own ADMA Biologics stock, we look forward to hearing from you.

To learn more about Scott+Scott, our attorneys, or complex case resolution, please visit www.scott-scott.com.

Attorney Advertising

View source version on businesswire.com: https://www.businesswire.com/news/home/20260615317156/en/

Scott+Scott Attorneys at Law LLP, an international securities and consumer rights litigation firm, is investigating whether the directors of ADMA Biologics (NASDAQ: ADMA) breached their fiduciary duties to ADMA’s shareholders.